Drug Trial Radar · NCT07314242
A Study to Investigate the Biomarkers of Hemay005 in Adult Participants With Moderate to Severe COPD
Last checked: Nov 19, 2026Latest source record: Jan 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Jan 1, 2026
Primary completion
Dec 31, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Ganzhou Hemay Pharmaceutical Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Jan 2, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Multicenter, Randomized, Double-blind, Single-dummy, positive drug and placebo-controlled, Parallel Group, Phase 2a Study to Evaluate the Efficacy and Safety of Hemay005 in Adults with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD).
Conditions
- COPD (Chronic Obstructive Pulmonary Disease)
Interventions
Hemay005 tabletsDrug
Subjects take Hemay005 tablets for 12 weeks.
Roflumilast Oral TabletDrug
Subjects take roflumilast tablet for 12 weeks.
Placebo tabletDrug
Subjects take placebo tablet for 12 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Sputum biomarkersTime frame: Change from baseline to week 4
- Sputum cell countTime frame: Change from baseline to week 4
- Blood BiomarkersTime frame: Change from baseline to week 4
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Tianjin Fourth Central Hospital
Tianjin, China
China People's Armed Police Force Characteristic Medical Center
Tianjin, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.